SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 226 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,110,015 | -3.3% | 76,533 | +5.4% | 0.00% | 0.0% |
| Q2 2023 | $2,182,386 | +1.6% | 72,601 | +22.5% | 0.00% | 0.0% |
| Q1 2023 | $2,147,352 | -20.2% | 59,270 | -21.4% | 0.00% | 0.0% |
| Q4 2022 | $2,690,338 | +101.2% | 75,423 | +91.0% | 0.00% | +100.0% |
| Q3 2022 | $1,337,000 | +31.5% | 39,496 | +12.3% | 0.00% | 0.0% |
| Q2 2022 | $1,017,000 | -63.0% | 35,179 | -58.6% | 0.00% | -50.0% |
| Q1 2022 | $2,747,000 | +0.7% | 84,980 | -9.2% | 0.00% | 0.0% |
| Q4 2021 | $2,728,000 | -24.5% | 93,555 | -31.0% | 0.00% | 0.0% |
| Q3 2021 | $3,615,000 | -1.3% | 135,528 | +13.9% | 0.00% | 0.0% |
| Q2 2021 | $3,664,000 | +55.6% | 118,993 | +32.3% | 0.00% | 0.0% |
| Q1 2021 | $2,355,000 | +0.1% | 89,961 | -3.8% | 0.00% | 0.0% |
| Q4 2020 | $2,352,000 | +15.2% | 93,485 | -4.6% | 0.00% | 0.0% |
| Q3 2020 | $2,042,000 | +68.5% | 97,990 | +92.0% | 0.00% | +100.0% |
| Q2 2020 | $1,212,000 | +33.6% | 51,026 | +1.2% | 0.00% | 0.0% |
| Q1 2020 | $907,000 | -70.6% | 50,444 | -45.9% | 0.00% | -66.7% |
| Q2 2019 | $3,084,000 | -1.1% | 93,189 | +4.8% | 0.00% | 0.0% |
| Q1 2019 | $3,117,000 | +15.8% | 88,958 | +9.8% | 0.00% | 0.0% |
| Q4 2018 | $2,692,000 | -33.2% | 81,048 | +1.3% | 0.00% | -25.0% |
| Q3 2018 | $4,030,000 | -14.8% | 80,047 | +1.3% | 0.00% | -20.0% |
| Q2 2018 | $4,731,000 | +30.7% | 79,047 | 0.0% | 0.01% | +25.0% |
| Q1 2018 | $3,620,000 | -35.2% | 79,047 | -43.4% | 0.00% | -33.3% |
| Q3 2017 | $5,583,000 | -45.9% | 139,563 | -41.7% | 0.01% | -45.5% |
| Q2 2017 | $10,319,000 | +15.4% | 239,425 | -16.2% | 0.01% | +22.2% |
| Q1 2017 | $8,941,000 | +43.6% | 285,664 | +15.9% | 0.01% | +28.6% |
| Q4 2016 | $6,225,000 | -8.3% | 246,540 | -10.2% | 0.01% | 0.0% |
| Q3 2016 | $6,790,000 | -1.8% | 274,557 | -19.1% | 0.01% | -12.5% |
| Q2 2016 | $6,916,000 | +202.0% | 339,509 | +126.1% | 0.01% | +166.7% |
| Q1 2016 | $2,290,000 | -27.9% | 150,172 | -33.7% | 0.00% | -25.0% |
| Q3 2015 | $3,176,000 | +1207.0% | 226,360 | +1480.7% | 0.00% | – |
| Q2 2015 | $243,000 | – | 14,320 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |